Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Following Phase II Failure, Teva Drops Investigation Of Glatiramer For ALS

This article was originally published in The Pink Sheet Daily

Executive Summary

Compound fails to meet primary and secondary trial endpoints.

You may also be interested in...



Another setback for Teva's ALS pipeline as talampanel tanks in Phase II

Teva's selective AMPA antagonist talampanel failed to meet the primary endpoint in a Phase II trial in amyotrophic lateral sclerosis, ending its prospects. The May 17 announcement comes just over two years after Teva terminated its lead project in ALS, a higher-dose formulation of glatiramer, the active ingredient in Teva's multiple sclerosis therapy Copaxone, also after a Phase II failure (1"The Pink Sheet" DAILY, March 13, 2008). The Phase II ALSTAR trial of talampanel enrolled 559 ALS patients randomized to one of two doses of talampanel or placebo for 52 weeks to determine if the drug could reduce disease-related functional deterioration. Talampanel failed to show an effect on the change from baseline in the revised ALS Functional Rating Scale, the primary outcome measure, Teva reported, although the study did demonstrate the drug to be safe

Another setback for Teva's ALS pipeline as talampanel tanks in Phase II

Teva's selective AMPA antagonist talampanel failed to meet the primary endpoint in a Phase II trial in amyotrophic lateral sclerosis, ending its prospects. The May 17 announcement comes just over two years after Teva terminated its lead project in ALS, a higher-dose formulation of glatiramer, the active ingredient in Teva's multiple sclerosis therapy Copaxone, also after a Phase II failure (1"The Pink Sheet" DAILY, March 13, 2008). The Phase II ALSTAR trial of talampanel enrolled 559 ALS patients randomized to one of two doses of talampanel or placebo for 52 weeks to determine if the drug could reduce disease-related functional deterioration. Talampanel failed to show an effect on the change from baseline in the revised ALS Functional Rating Scale, the primary outcome measure, Teva reported, although the study did demonstrate the drug to be safe

High Copaxone Dose Fails To Show Superiority In MS, Teva Says

In Phase III, 40 mg dose did not reduce relapse rate in patients over the approved 20 mg strength.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel